[go: up one dir, main page]

WO2001091798A3 - Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers - Google Patents

Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers Download PDF

Info

Publication number
WO2001091798A3
WO2001091798A3 PCT/EP2001/006106 EP0106106W WO0191798A3 WO 2001091798 A3 WO2001091798 A3 WO 2001091798A3 EP 0106106 W EP0106106 W EP 0106106W WO 0191798 A3 WO0191798 A3 WO 0191798A3
Authority
WO
WIPO (PCT)
Prior art keywords
prodrug compounds
activated prodrug
methods
biologically active
tumor activated
Prior art date
Application number
PCT/EP2001/006106
Other languages
English (en)
Other versions
WO2001091798A2 (fr
Inventor
Andre Trouet
Vincent Dubois
Arnold Oronsky
Original Assignee
Univ Catholique Louvain
Andre Trouet
Vincent Dubois
Arnold Oronsky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Catholique Louvain, Andre Trouet, Vincent Dubois, Arnold Oronsky filed Critical Univ Catholique Louvain
Priority to AU2001279630A priority Critical patent/AU2001279630A1/en
Priority to JP2001587810A priority patent/JP2003534387A/ja
Priority to CA002408103A priority patent/CA2408103A1/fr
Priority to US10/296,954 priority patent/US20040014652A1/en
Priority to EP01957808A priority patent/EP1286700A2/fr
Publication of WO2001091798A2 publication Critical patent/WO2001091798A2/fr
Publication of WO2001091798A3 publication Critical patent/WO2001091798A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés de promédicaments, des compositions renfermant les composés de promédicaments précités, des procédés de fabrication des composés de promédicaments précités et des procédés d'utilisation de ces derniers. Les composés de promédicaments de l'invention comprennent une entité biologiquement active liée à un fragment masquant via un fragment de liaison. Les composés de promédicaments de l'invention sont sélectivement activés sur les cellules cibles ou à proximité de celles-ci et ils présentent une toxicité inférieure et, éventuellement, une demi-vie sérique ou in vivo plus longue que l'entité biologiquement active correspondante pure.
PCT/EP2001/006106 2000-06-01 2001-05-29 Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers WO2001091798A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001279630A AU2001279630A1 (en) 2000-06-01 2001-05-29 Tumor activated prodrug compounds
JP2001587810A JP2003534387A (ja) 2000-06-01 2001-05-29 腫瘍活性化プロドラッグ化合物、並びにこれらの製造方法及び使用方法
CA002408103A CA2408103A1 (fr) 2000-06-01 2001-05-29 Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers
US10/296,954 US20040014652A1 (en) 2000-06-01 2001-05-29 Tumor activated prodrug compounds and methods of making and using the same
EP01957808A EP1286700A2 (fr) 2000-06-01 2001-05-29 Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US20899600P 2000-06-01 2000-06-01
US60/208,996 2000-06-01
EP00870130 2000-06-15
EP00870130.2 2000-06-15
EP00870306.8 2000-12-18
EP00870306 2000-12-18
EP01957808A EP1286700A2 (fr) 2000-06-01 2001-05-29 Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers

Publications (2)

Publication Number Publication Date
WO2001091798A2 WO2001091798A2 (fr) 2001-12-06
WO2001091798A3 true WO2001091798A3 (fr) 2002-12-05

Family

ID=27440072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/006106 WO2001091798A2 (fr) 2000-06-01 2001-05-29 Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers

Country Status (2)

Country Link
EP (1) EP1286700A2 (fr)
WO (1) WO2001091798A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169321B2 (en) 2007-08-22 2015-10-27 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
WO2001062300A2 (fr) * 2000-02-24 2001-08-30 Genentech, Inc. Therapie par promedicaments actives par une caspase
CA2423850C (fr) 2000-10-09 2017-07-04 Isis Innovation Limited Anticorps therapeutiques
EP1349577A2 (fr) * 2000-11-06 2003-10-08 Asilomar Pharmaceuticals, Inc. Composes pour administration intracellulaire de fractions therapeutiques a des cellules nerveuses
WO2002060488A1 (fr) * 2001-01-30 2002-08-08 Universite Catholique De Louvain Composes antitumoraux
KR100468316B1 (ko) * 2002-01-29 2005-01-27 주식회사 웰진 Ｄｎａ의 세포 또는 조직 내 전달 효율을 높이는 펩타이드
SI1537204T1 (sl) * 2002-08-23 2010-06-30 Gabriele Prof Dr Multhoff Granzim b kot povzročitelj apoptoze odvisen od peptida Hsp Hsp v tumorskih celicah
US20050043215A1 (en) * 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
FR2858936A1 (fr) * 2003-08-22 2005-02-25 Diatos Potentialisation de l'activation de prodrogues de haut poids moleculaire
WO2005115457A2 (fr) * 2004-05-10 2005-12-08 University Of Utah Research Foundation Ciblage actif et passif combines d'agents biologiquement actifs
EP1674113A1 (fr) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugués de l'IGF-1 et du poly(éthylène glycol)
US7214767B2 (en) * 2005-05-25 2007-05-08 Hiroshi Kanno VHL peptide
EP2433642B1 (fr) * 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Protéases modifiées inhibant l'activation de complément
JP2009529522A (ja) * 2006-03-10 2009-08-20 ディアト 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
US8552158B2 (en) 2006-08-31 2013-10-08 Hoffmann-La Roche Inc. Method for the production of insulin-like growth factor-1
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
CA2696263C (fr) 2007-08-15 2017-06-13 Bing Liu Anticorps monospecifiques et multispecifiques, et procedes d'utilisation
AU2016213702C1 (en) * 2007-08-22 2018-11-29 Cytomx Therapeutics, Inc. Activatable binding polypeptides and methods of identification and use thereof
AU2013202755B2 (en) * 2007-08-22 2016-05-12 Cytomx Therapeutics, Inc. Activatable binding polypeptides and methods of identification and use thereof
EP3543256A1 (fr) * 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Compositions d anticorps modifiées et leurs procédés de production et d'utilisation
KR20100083632A (ko) * 2009-01-14 2010-07-22 울산대학교 산학협력단 표적 단백질 분해효소 감응형 항암제 전구체
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
WO2013163631A2 (fr) 2012-04-27 2013-10-31 Cytomx Therapeutics, Inc. Anticorps activables liant le récepteur du facteur de croissance épidermique et leurs procédés d'utilisation
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
BR112014031689A2 (pt) 2012-06-22 2017-07-25 Cytomx Therapeutics Inc anticorpos reativos cruzados anti-jagged 1/jagged 2, anticorpos anti-jagged ativáveis e métodos de uso deles
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
RU2015132436A (ru) 2013-01-04 2017-02-09 Сайтомкс Терапьютикс, Инк. Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления
AU2014274982B2 (en) * 2013-06-04 2019-12-05 Cytomx Therapeutics, Inc Compositions and methods for conjugating activatable antibodies
PL3406633T3 (pl) 2013-07-25 2022-05-23 Cytomx Therapeutics Inc. Przeciwciała wieloswoiste, aktywowalne przeciwciała wieloswoiste i metody ich stosowania
AU2014320332B2 (en) * 2013-09-12 2017-08-03 Dsm Ip Assets B.V. Ocular device
NZ756892A (en) 2013-09-25 2022-05-27 Cytomx Therapeutics Inc Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (fr) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Anticorps qui se lient à des anticorps activables et leurs procédés d'utilisation
CN114106099B (zh) 2014-01-31 2024-05-24 西托姆克斯治疗公司 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
US10669337B2 (en) 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
KR20180011127A (ko) 2015-05-04 2018-01-31 싸이톰스 테라퓨틱스, 인크. 항cd71 항체, 활성화 가능한 항cd71 항체, 및 이들의 사용 방법
WO2016179335A1 (fr) 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anticorps anti-itga3, anticorps anti-itga3 activables, et leurs méthodes d'utilisation
SG10202110908WA (en) 2015-05-04 2021-11-29 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
EP3535300A1 (fr) 2016-11-03 2019-09-11 Bristol-Myers Squibb Company Anticorps anti-ctla-4 activables et leurs utilisations
US11230610B2 (en) 2016-12-09 2022-01-25 Seagen Inc. Bivalent antibodies masked by coiled coils
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
TWI850203B (zh) 2017-10-14 2024-08-01 美商Ｃｙｔｏｍｘ生物製藥公司 抗體、可活化之抗體、雙特異性抗體、和雙特異性可活化之抗體、及其使用方法
JP2021530507A (ja) 2018-07-18 2021-11-11 マンザニータ ファーマシューティカルズ，インク． 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法
CN113271956B (zh) 2018-12-06 2025-04-29 西托姆克斯治疗公司 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法
WO2021207657A1 (fr) 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions contenant des anticorps activables
US11365233B2 (en) 2020-04-10 2022-06-21 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
EP4267188A1 (fr) 2020-12-22 2023-11-01 Cobiores NV Composés comprenant une fraction tétrapeptidique
WO2022167664A1 (fr) 2021-02-07 2022-08-11 Cobiores Nv Composés comprenant une fraction tétrapeptidique
MX2023010840A (es) 2021-03-16 2023-10-26 Cytomx Therapeutics Inc Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005863A1 (fr) * 1994-08-19 1996-02-29 La Region Wallonne Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005863A1 (fr) * 1994-08-19 1996-02-29 La Region Wallonne Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CALICETI P ET AL: "PREPARATION AND PROPERTIES OF MONOMETHOXY POLY(ETHYLENE GLYCOL) DOXORUBICIN CONJUGATES LINKED BY AN AMINO ACID OR A PEPTIDE AS SPACER", FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 48, no. 7, 1 July 1993 (1993-07-01), pages 919 - 932, XP000371926, ISSN: 0014-827X *
CHARI R.V.J.: "Targeted delivery of chemotherapeutics: Tumor - activated prodrug therapy.", ADVANCED DRUG DELIVERY REVIEWS, (6 APR 1998) 31/1-2 (89-104)., XP002204748 *
CHARI, R. V. J. (1) ET AL: "Integration of SB-408075 into combination treatments of human colon xenograft models of SCID mice.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 2000) NO. 41, PP. 291. MEETING INFO.: 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CALIFORNIA, USA APRIL 01-05, 2000, XP002204745 *
CHARI, R. V. J. ET AL: "C242-DM1: A tumor - activated prodrug that shows exceptional activity in human colon tumor xenograft models at non-toxic doses.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1998) VOL. 39, PP. 643. MEETING INFO.: 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NEW ORLEANS, LOUISIANA, USA MARCH 28-APRIL 1, 1998 AMERICAN, XP002204746 *
LAMBERT, J. M. ET AL: "Pharmacokinetics, in vivo stability, and toxicity of the tumor - activated prodrug, C242-DM1, a novel colorectal cancer agent.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1998) VOL. 39, PP. 522. MEETING INFO.: 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NEW ORLEANS, LOUISIANA, USA MARCH 28-APRIL 1, 1998 AMERICAN, XP002204747 *
NICHIFOR, MARIETA ET AL: "Macromolecular prodrugs of 5-fluorouracil. 2: Enzymic degradation", J. CONTROLLED RELEASE (1996), 39(1), 79-92, XP002204749 *
TROUET A ET AL: "Extracellularly tumor - activated prodrugs fo the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.", CANCER RESEARCH, (2001 APR 1) 61 (7) 2843-6., XP002204750 *
TROUET, ANDRE (1) ET AL: "CPI-0004Na: An extracellularly tumor - activated prodrug of doxorubicin.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 2000) NO. 41, PP. 522. MEETING INFO.: 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CALIFORNIA, USA APRIL 01-05, 2000, XP002204744 *
WIEBE, L. I. ET AL: "Concepts for the design of anti-HIV nucleoside prodrugs for treating cephalic HIV infection", ADVANCED DRUG DELIVERY REVIEWS (1999), 39(1-3), 63-80, XP002204743 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169321B2 (en) 2007-08-22 2015-10-27 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof

Also Published As

Publication number Publication date
WO2001091798A2 (fr) 2001-12-06
EP1286700A2 (fr) 2003-03-05

Similar Documents

Publication Publication Date Title
WO2001091798A3 (fr) Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers
WO1999042079A3 (fr) Compositions de ciment antimicrobiennes pour prothese dentaire
EP2338513A3 (fr) Conjugués polymères liberables fondés sur des lieurs biodegradables aliphatiques
PT1157037E (pt) Conjugados de gcsf
WO2004108070A3 (fr) Conjugues polymeres liberables fondes sur des lieurs biodegradables aliphatiques
AU2002210993A1 (en) Medicinal compositions for concominant use as anticancer agents
DE69531342D1 (de) Avidin-biotin immunokonjugate
DZ2646A1 (fr) Dérivés de thiénopyrimidine et thiénopyridine utiles comme agents anticancéreux et compositions les contenant.
DK1075282T3 (da) PEG-LHRH-analog-konjugater
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
WO2000066104A3 (fr) Composes inhibant ace-2 et leurs procedes d'utilisation
WO2004008101A3 (fr) Utilisation d'agents de liaison isocyanate pour produire des conjugues biopolymere-substance active hydrolysables
WO2000018439A3 (fr) Utilisation de marqueurs de neoangiogenese pour diagnostiquer et traiter des tumeurs
PT1140808E (pt) Formulacoes de pesticidas contendo tensioactivos de ester de hemissulfato de tristirilfenol alcoxilado, neutralizados com amina alcoxilada
WO2002059368A8 (fr) Expression specifique de la mucine utilisee comme marqueur du cancer pancreatique
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
AU4041099A (en) Use of spinosynes as soil insecticides
WO2000053231A3 (fr) Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes
AU2001270626A1 (en) Floating type formulation of agricultural agents
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
WO2003020963A3 (fr) Proteines impliquees dans le diabete de type 2
AU2002214876A1 (en) Combination preparation of a biological response modifier and an anticancer agent and uses thereof
AU6132499A (en) Novel mercaptans and disulfides
DE60029084D1 (de) Neue depsipeptid-verbindung
BR0014192A (pt) Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2408103

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 587810

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001957808

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001957808

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10296954

Country of ref document: US